Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$64.02
0.000.00%
Pre-Market: 6:58 PM EDT
Comments
Loading...
Halozyme Therapeutics Analyst Ratings and Price Targets | NASDAQ:HALO | Benzinga
Halozyme Therapeutics Inc has a consensus price target of $58.45 based on the ratings of 12 analysts. The high is $75 issued by Benchmark on February 20, 2025. The low is $42 issued by SVB Leerink on March 16, 2023. The 3 most-recent analyst ratings were released by Benchmark, HC Wainwright & Co., and HC Wainwright & Co. on February 20, 2025, February 19, 2025, and February 4, 2025, respectively. With an average price target of $72.33 between Benchmark, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 12.99% upside for Halozyme Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
Wells Fargo
Piper Sandler
JMP Securities
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Halozyme Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/06/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor45% | — | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | 17.15% | Benchmark | Robert Wasserman50% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 02/19/2025 | Buy Now | 12.46% | HC Wainwright & Co. | Mitchell Kapoor45% | $70 → $72 | Maintains | Buy | Get Alert |
| 02/04/2025 | Buy Now | 9.34% | HC Wainwright & Co. | Mitchell Kapoor45% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | -10.97% | Wells Fargo | Mohit Bansal73% | $62 → $57 | Maintains | Equal-Weight | Get Alert |
| 01/10/2025 | Buy Now | -17.21% | Piper Sandler | Joseph Catanzaro42% | $52 → $53 | Maintains | Neutral | Get Alert |
| 01/10/2025 | Buy Now | 9.34% | HC Wainwright & Co. | Mitchell Kapoor45% | $68 → $70 | Maintains | Buy | Get Alert |
| 12/30/2024 | Buy Now | 6.22% | HC Wainwright & Co. | Mitchell Kapoor45% | $68 → $68 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | 6.22% | HC Wainwright & Co. | Mitchell Kapoor45% | $68 → $68 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | 6.22% | HC Wainwright & Co. | Mitchell Kapoor45% | $68 → $68 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2024 | Buy Now | 6.22% | HC Wainwright & Co. | Mitchell Kapoor45% | $68 → $68 | Reiterates | Buy → Buy | Get Alert |
| 11/04/2024 | Buy Now | -18.78% | Piper Sandler | Joseph Catanzaro42% | $51 → $52 | Maintains | Neutral | Get Alert |
| 11/01/2024 | Buy Now | 14.03% | JMP Securities | Jason Butler56% | $72 → $73 | Maintains | Market Outperform | Get Alert |
| 11/01/2024 | Buy Now | 6.22% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $68 | Maintains | Buy | Get Alert |
| 10/25/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 10/07/2024 | Buy Now | -3.16% | Wells Fargo | Mohit Bansal73% | $58 → $62 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 10/04/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2024 | Buy Now | -10.97% | JP Morgan | Jessica Fye68% | $52 → $57 | Downgrade | Overweight → Neutral | Get Alert |
| 09/16/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | -6.28% | Benchmark | Robert Wasserman50% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 1.53% | TD Cowen | Brendan Smith36% | $59 → $65 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | -0.03% | Morgan Stanley | Vikram Purohit38% | $59 → $64 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | -18.78% | JP Morgan | Jessica Fye68% | $53 → $52 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | -23.46% | Goldman Sachs | Graig Suvannavejh55% | $44 → $49 | Maintains | Neutral | Get Alert |
| 07/16/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 06/25/2024 | Buy Now | -6.28% | Benchmark | Robert Wasserman50% | $50 → $60 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2024 | Buy Now | -20.34% | Piper Sandler | Joseph Catanzaro42% | $48 → $51 | Downgrade | Overweight → Neutral | Get Alert |
| 06/07/2024 | Buy Now | -9.4% | Wells Fargo | Mohit Bansal73% | $48 → $58 | Maintains | Overweight | Get Alert |
| 06/07/2024 | Buy Now | 1.53% | HC Wainwright & Co. | Mitchell Kapoor45% | $50 → $65 | Maintains | Buy | Get Alert |
| 06/04/2024 | Buy Now | -21.9% | HC Wainwright & Co. | Mitchell Kapoor45% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2024 | Buy Now | -21.9% | HC Wainwright & Co. | Mitchell Kapoor45% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 10.9% | JMP Securities | Jason Butler56% | $72 → $71 | Maintains | Market Outperform | Get Alert |
| 05/08/2024 | Buy Now | -21.9% | HC Wainwright & Co. | Mitchell Kapoor45% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | -21.9% | HC Wainwright & Co. | Mitchell Kapoor45% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | -21.9% | HC Wainwright & Co. | Mitchell Kapoor45% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | -21.9% | HC Wainwright & Co. | Mitchell Kapoor45% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | -21.9% | Benchmark | Robert Wasserman50% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | -15.65% | TD Cowen | Brendan Smith36% | → $54 | Initiates | → Outperform | Get Alert |
| 02/21/2024 | Buy Now | 12.46% | JMP Securities | Jason Butler56% | $72 → $72 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/21/2024 | Buy Now | -21.9% | HC Wainwright & Co. | Mitchell Kapoor45% | $48 → $50 | Maintains | Buy | Get Alert |
| 01/19/2024 | Buy Now | -25.02% | HC Wainwright & Co. | Mitchell Kapoor45% | $48 → $48 | Reiterates | Buy → Buy | Get Alert |
| 01/19/2024 | Buy Now | -21.9% | Benchmark | Robert Wasserman50% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/18/2024 | Buy Now | 12.46% | JMP Securities | Jason Butler56% | $72 → $72 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/18/2024 | Buy Now | -37.52% | Goldman Sachs | Graig Suvannavejh55% | $45 → $40 | Maintains | Neutral | Get Alert |
| 01/18/2024 | Buy Now | -25.02% | HC Wainwright & Co. | Mitchell Kapoor45% | $61 → $48 | Maintains | Buy | Get Alert |
| 12/26/2023 | Buy Now | -7.84% | Morgan Stanley | Vikram Purohit38% | $61 → $59 | Maintains | Overweight | Get Alert |
| 10/20/2023 | Buy Now | -21.9% | Benchmark | Robert Wasserman50% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 10/19/2023 | Buy Now | -4.72% | HC Wainwright & Co. | Mitchell Kapoor45% | $60 → $61 | Maintains | Buy | Get Alert |
| 10/09/2023 | Buy Now | -6.28% | HC Wainwright & Co. | Mitchell Kapoor45% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | -6.28% | HC Wainwright & Co. | Mitchell Kapoor45% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2023 | Buy Now | -6.28% | HC Wainwright & Co. | Mitchell Kapoor45% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | -6.28% | HC Wainwright & Co. | Mitchell Kapoor45% | $61 → $60 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | -4.72% | Morgan Stanley | Vikram Purohit38% | $60 → $61 | Maintains | Overweight | Get Alert |
| 07/24/2023 | Buy Now | -4.72% | HC Wainwright & Co. | Mitchell Kapoor45% | → $61 | Initiates | → Buy | Get Alert |
| 07/24/2023 | Buy Now | -29.71% | Goldman Sachs | Graig Suvannavejh55% | $43 → $45 | Downgrade | Buy → Neutral | Get Alert |
| 05/10/2023 | Buy Now | 3.09% | JMP Securities | Jason Butler56% | → $66 | Reiterates | → Market Outperform | Get Alert |
| 05/10/2023 | Buy Now | -6.28% | Morgan Stanley | Vikram Purohit38% | $64 → $60 | Maintains | Overweight | Get Alert |
| 05/10/2023 | Buy Now | -28.15% | Piper Sandler | Joseph Catanzaro42% | → $46 | Upgrade | Neutral → Overweight | Get Alert |
| 03/27/2023 | Buy Now | -9.4% | Berenberg | Caroline Palomeque60% | → $58 | Reinstates | → Buy | Get Alert |
| 03/17/2023 | Buy Now | -25.02% | Wells Fargo | Mohit Bansal73% | $55 → $48 | Maintains | Overweight | Get Alert |
| 03/16/2023 | Buy Now | -34.4% | SVB Leerink | David Risinger74% | → $42 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/16/2023 | Buy Now | -14.09% | Wells Fargo | Mohit Bansal73% | $65 → $55 | Maintains | Overweight | Get Alert |
| 03/06/2023 | Buy Now | -0.03% | Morgan Stanley | Vikram Purohit38% | $65 → $64 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -18.78% | JP Morgan | Jessica Fye68% | $54 → $52 | Maintains | Overweight | Get Alert |
| 02/22/2023 | Buy Now | 3.09% | JMP Securities | Jason Butler56% | $62 → $66 | Reiterates | → Market Outperform | Get Alert |
| 01/11/2023 | Buy Now | -4.72% | SVB Leerink | David Risinger74% | $62 → $61 | Maintains | Outperform | Get Alert |
| 12/21/2022 | Buy Now | 1.53% | Morgan Stanley | Vikram Purohit38% | $53 → $65 | Maintains | Overweight | Get Alert |
| 12/08/2022 | Buy Now | 6.22% | Benchmark | Robert Wasserman50% | $55 → $68 | Maintains | Buy | Get Alert |
| 11/28/2022 | Buy Now | 1.53% | Wells Fargo | Mohit Bansal73% | → $65 | Initiates | → Overweight | Get Alert |
| 11/22/2022 | Buy Now | -15.65% | JP Morgan | Jessica Fye68% | $53 → $54 | Maintains | Overweight | Get Alert |
| 11/14/2022 | Buy Now | -3.16% | SVB Leerink | David Risinger74% | $52 → $62 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | -3.16% | JMP Securities | Jason Butler56% | $60 → $62 | Maintains | Market Outperform | Get Alert |
| 09/09/2022 | Buy Now | -21.9% | Morgan Stanley | Andrew Galler32% | → $50 | Initiates | → Overweight | Get Alert |
| 05/26/2022 | Buy Now | -6.28% | Goldman Sachs | Graig Suvannavejh55% | $48 → $60 | Maintains | Buy | Get Alert |
| 05/11/2022 | Buy Now | -9.4% | JMP Securities | Jason Butler56% | $55 → $58 | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for Halozyme Therapeutics (HALO) stock?
The latest price target for Halozyme Therapeutics (NASDAQ:HALO) was reported by HC Wainwright & Co. on March 6, 2025. The analyst firm set a price target for $0.00 expecting HALO to fall to within 12 months (a possible -100.00% downside). 42 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Halozyme Therapeutics (HALO)?
The latest analyst rating for Halozyme Therapeutics (NASDAQ:HALO) was provided by HC Wainwright & Co., and Halozyme Therapeutics reiterated their buy rating.
When was the last upgrade for Halozyme Therapeutics (HALO)?
The last upgrade for Halozyme Therapeutics Inc happened on May 10, 2023 when Piper Sandler raised their price target to $46. Piper Sandler previously had a neutral for Halozyme Therapeutics Inc.
When was the last downgrade for Halozyme Therapeutics (HALO)?
The last downgrade for Halozyme Therapeutics Inc happened on October 7, 2024 when Wells Fargo changed their price target from $58 to $62 for Halozyme Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Halozyme Therapeutics (HALO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.
Is the Analyst Rating Halozyme Therapeutics (HALO) correct?
While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a reiterated with a price target of $0.00 to $0.00. The current price Halozyme Therapeutics (HALO) is trading at is $64.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.